IDH1 and IDH2: not your typical oncogenes

Area of Science:

• Biochemistry
• Cancer Biology
• Enzymology

Background:

• Oncogenes typically promote cancer by enhancing their normal cellular functions.
• Mutations in isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) are frequently observed in various cancers.
• These IDH mutations appear to contradict the typical oncogene model by decreasing the enzyme's native catalytic activity.

Discussion:

• The study by Ward et al. investigates the functional consequences of IDH1 and IDH2 mutations.
• It challenges the notion that reduced native enzyme activity is the sole mechanism of oncogenesis for these mutations.
• The research focuses on identifying alternative enzymatic functions that may contribute to cancer development.

Key Insights:

• The research identifies a novel, neomorphic enzyme activity associated with mutated IDH1 and IDH2.
• This neomorphic activity, distinct from the enzyme's normal function, is proposed as the oncogenic driver.
• This finding redefines the understanding of how IDH mutations contribute to tumorigenesis.

Outlook:

• Further research is needed to fully elucidate the biochemical pathways regulated by this neomorphic activity.
• Targeting this specific neomorphic function could offer new therapeutic strategies for IDH-mutated cancers.
• Understanding this altered enzymatic function is crucial for developing more effective cancer treatments.